Xvivo Perfusion AB

XVIVO

Equity

ISIN SE0004840718 / Valor 19661174

NASDAQ Nordic Exchange Stockholm, Equities (2024-09-18)

SEK 492.00-3.15%

Xvivo Perfusion AB
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Xvivo Perfusion AB is a medical technology company founded in 1998 and headquartered in Gothenburg, Sweden. The company specializes in developing solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. Xvivo is dedicated to extending the life of major organs to help transplant teams save more lives. Their solutions enable clinicians and researchers to advance transplantation medicine. Xvivo is listed on Nasdaq and has offices and research sites on three continents.

Summarized from source with an LLMView SourceSector: Healthcare

Net Sales Growth

In the second quarter of 2024, Xvivo Perfusion AB reported net sales amounting to SEK 210.3 million, up from SEK 154.6 million in the same period the previous year. This represents a growth of 36 percent in SEK and 35 percent in local currencies, with all growth being organic.

Operating Income

Xvivo Perfusion AB's operating income (EBIT) for Q2 2024 amounted to SEK 33.4 million, a significant increase from SEK 3.8 million in Q2 2023. Adjusted EBIT also saw a rise, reaching SEK 33.4 million compared to SEK 15.1 million in the previous year.

EBITDA Margin

The company's operating income before depreciation and amortization (EBITDA) for the second quarter of 2024 was SEK 51.1 million, up from SEK 17.2 million in Q2 2023. This corresponds to an EBITDA margin of 24 percent, compared to 11 percent in the previous year.

Net Profit

Xvivo Perfusion AB's net profit for Q2 2024 increased to SEK 27.2 million, up from SEK 6.9 million in the same quarter of the previous year. Earnings per share also rose to SEK 0.86 from SEK 0.23.

Cash Flow

Cash flow from operating activities for the second quarter of 2024 increased to SEK 24.7 million, compared to SEK 15.7 million in Q2 2023. However, total cash flow amounted to SEK -27.2 million, impacted by investments in R&D projects, production facilities, and machine installations at clinics.

Summarized from source with an LLMView Source

Key figures

73.5%1Y

15.2%3Y

177%5Y

Performance

47.4%1Y

50.8%3Y

48.7%5Y

Volatility